Insulet CorporationPODD
▲ PositiveCapitalrelevance
CEO's insider purchase signals confidence after stock decline.
Impact on assets 1
Biotech & Genomic Medicine
Insulet CorporationInsulet Corporation President and CEO Ashley McEvoy purchased 1,100 shares of common stock on August 21, 2026, in an open-market transaction valued at $162,217. The shares were acquired at prices ranging from $147.42 to $147.62, resulting in a weighted average purchase price of $147.47. Following the purchase, McEvoy directly holds 23,731 shares and indirectly holds 4 shares through a trust, bringing her total position to 23,735 shares valued at $3.52 million based on the August 21 closing price of $148.16. The company, which develops the Omnipod insulin delivery platform, reported trailing twelve-month revenue of $3.1 billion and net income of $375.3 million. Insulet's latest quarterly sales grew 23% year over year on a constant currency basis, and management expects full-year revenue growth of about 21%.
Insulet CorporationCEO's insider purchase signals confidence after stock decline.